You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK)評估SCB-2019作為異源新冠加強針對既往免疫接種滅活、mRNA或病毒載體疫苗效果的III期試驗完成首批受試者接種

格隆匯6月14日丨三葉草生物-B(02197.HK)發佈公吿,一項評估三葉草生物候選疫苗SCB-2019(CpG 1018╱鋁佐劑)作為新冠加強針的安全性和免疫原性的III期研究的首批受試者完成接種。該批受試者既往已接種兩劑克爾來福TM(科興滅活疫苗)、Comirnaty®(輝瑞mRNA疫苗)或Vaxzevria®(阿斯利康病毒載體疫苗)。

這項新研究將為評估SCB-2019(CpG 1018╱鋁佐劑)作為潛在的通用新冠候選加強針提供更多證據。2022年4月公佈的另一項研究數據顯示,在既往接種2劑阿斯利康新冠疫苗的個體中接種SCB-2019(CpG 1018╱鋁佐劑)異源加強針,與接種3劑阿斯利康新冠疫苗的個體相比,針對野生型毒株和值得關注的變異株(包括奧密克戎)誘導了更快速的應答和更高的中和抗體水平。公司計劃一旦獲得這些通用新冠加強針數據,會將其納入註冊申請中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account